Thrombocytopenia, Neonatal Alloimmune
Oncology·MeSH: Thrombocytopenia, Neonatal Alloimmune
Prevalence
30.0 / 100K
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(2)
Frequently asked questions
How many drugs are in development for Thrombocytopenia, Neonatal Alloimmune?
BioSniper tracks 2 drugs in development for Thrombocytopenia, Neonatal Alloimmune across 2 companies.
How many clinical trials target Thrombocytopenia, Neonatal Alloimmune?
There are 1 clinical trial targeting Thrombocytopenia, Neonatal Alloimmune tracked by BioSniper.
What is the prevalence of Thrombocytopenia, Neonatal Alloimmune?
The estimated prevalence of Thrombocytopenia, Neonatal Alloimmune is approximately 30.0 per 100,000 population.
Deep-dive into Thrombocytopenia, Neonatal Alloimmune
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis